Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 135, Issue 1, Pages 39-48
Publisher
Springer Nature
Online
2012-04-19
DOI
10.1007/s10549-012-2067-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
- (2012) Michael Untch et al. LANCET ONCOLOGY
- Dual HER2-targeted approaches in HER2-positive breast cancer
- (2011) Eugene R. Ahn et al. BREAST CANCER RESEARCH AND TREATMENT
- Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients
- (2011) Filippo Montemurro et al. CANCER
- Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
- (2011) Joan T. Garrett et al. CANCER BIOLOGY & THERAPY
- Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient
- (2011) S. Gluck et al. CLINICAL CANCER RESEARCH
- Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
- (2011) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
- (2010) M Knauer et al. BRITISH JOURNAL OF CANCER
- A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers
- (2010) J. L. Parra-Palau et al. CANCER RESEARCH
- Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance
- (2010) A. F. Leary et al. CLINICAL CANCER RESEARCH
- Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts
- (2010) Mothaffar F. Rimawi et al. CLINICAL CANCER RESEARCH
- Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer
- (2010) Rohit Bhargava et al. MODERN PATHOLOGY
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
- (2009) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer
- (2009) Virginia G. Kaklamani et al. BIOMARKERS
- Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen
- (2009) Gauri Sabnis et al. CANCER RESEARCH
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
- (2009) E. A. Mittendorf et al. CLINICAL CANCER RESEARCH
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene-Expression Signatures in Breast Cancer
- (2009) Christos Sotiriou et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
- (2008) S. Massarweh et al. CANCER RESEARCH
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen
- (2008) Antoni Hurtado et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now